179 related articles for article (PubMed ID: 33800528)
1. Early Administration of Convalescent Plasma Improves Survival in Patients with Hematological Malignancies and COVID-19.
Biernat MM; Kolasińska A; Kwiatkowski J; Urbaniak-Kujda D; Biernat P; Janocha-Litwin J; Szymczyk-Nużka M; Bursy D; Kalicińska E; Simon K; Mazur G; Wróbel T
Viruses; 2021 Mar; 13(3):. PubMed ID: 33800528
[TBL] [Abstract][Full Text] [Related]
2. Convalescent plasma therapy for severe Covid-19 in patients with hematological malignancies.
Jeyaraman P; Agrawal N; Bhargava R; Bansal D; Ahmed R; Bhurani D; Bansal S; Rastogi N; Borah P; Naithani R;
Transfus Apher Sci; 2021 Jun; 60(3):103075. PubMed ID: 33574010
[TBL] [Abstract][Full Text] [Related]
3. Early administration of remdesivir plus convalescent plasma therapy is effective to treat COVID-19 pneumonia in B-cell depleted patients with hematological malignancies.
Magyari F; Pinczés LI; Páyer E; Farkas K; Ujfalusi S; Diószegi Á; Sik M; Simon Z; Nagy G; Hevessy Z; Nagy B; Illés Á
Ann Hematol; 2022 Oct; 101(10):2337-2345. PubMed ID: 35836007
[TBL] [Abstract][Full Text] [Related]
4. Use of convalescent plasma in COVID-19 patients with immunosuppression.
Senefeld JW; Klassen SA; Ford SK; Senese KA; Wiggins CC; Bostrom BC; Thompson MA; Baker SE; Nicholson WT; Johnson PW; Carter RE; Henderson JP; Hartman WR; Pirofski LA; Wright RS; Fairweather L; Bruno KA; Paneth NS; Casadevall A; Joyner MJ
Transfusion; 2021 Aug; 61(8):2503-2511. PubMed ID: 34036587
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome.
Levy I; Lavi A; Zimran E; Grisariu S; Aumann S; Itchaki G; Berger T; Raanani P; Harel R; Aviv A; Lavi N; Zuckerman T; Shvidel L; Jarchowsky O; Ellis M; Herzog Tzarfati K; Koren-Michowitz M; Sherf Y; Levi I; Sofer O; Shpilberg O; Dally N; Suriu C; Braester A; Ben Barouch S; Leiba M; Goldstein D; Sarid N; Yeganeh S; Halloun J; Mittelman M; Tadmor T
Leuk Lymphoma; 2021 Dec; 62(14):3384-3393. PubMed ID: 34405767
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of COVID-19 infection with convalescent plasma in B-cell-depleted patients may promote cellular immunity.
Kremer AE; Kremer AN; Willam C; Völkl S; Verhagen J; Achenbach S; van der Meijden ED; Lang V; Aigner M; Maier C; Tenbusch M; Korn K; Lutzny-Geier G; Spoerl S; Strauß R; Vetter M; Überla K; Neurath MF; Mackensen A; Schiffer M; Hackstein H
Eur J Immunol; 2021 Oct; 51(10):2478-2484. PubMed ID: 34350584
[TBL] [Abstract][Full Text] [Related]
7. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
[TBL] [Abstract][Full Text] [Related]
8. [SARS-COV-2 infection in patients with hematological malignancies and transplants].
Herrera F; Bues F; Rojas R; Temporiti E; Videla C; Dupont J; Bonvehí P
Medicina (B Aires); 2021; 81(3):396-400. PubMed ID: 34137699
[TBL] [Abstract][Full Text] [Related]
9. Convalescent plasma for the treatment of patients with severe coronavirus disease 2019: A preliminary report.
Omrani AS; Zaqout A; Baiou A; Daghfal J; Elkum N; Alattar RA; Bakdach D; Abusriwil H; Mostafa AM; Alhariri B; Ambra N; Khatib M; Eldeeb AM; Merenkov Z; Fawzi Z; Hmissi SM; Hssain AA; Coyle PV; Alsoub H; Almaslamani MA; Alkhal A
J Med Virol; 2021 Mar; 93(3):1678-1686. PubMed ID: 32965715
[TBL] [Abstract][Full Text] [Related]
10. Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors.
Kunze KL; Johnson PW; van Helmond N; Senefeld JW; Petersen MM; Klassen SA; Wiggins CC; Klompas AM; Bruno KA; Mills JR; Theel ES; Buras MR; Golafshar MA; Sexton MA; Diaz Soto JC; Baker SE; Shepherd JRA; Verdun NC; Marks P; Paneth NS; Fairweather D; Wright RS; van Buskirk CM; Winters JL; Stubbs JR; Senese KA; Pletsch MC; Buchholtz ZA; Rea RF; Herasevich V; Whelan ER; Clayburn AJ; Larson KF; Ripoll JG; Andersen KJ; Lesser ER; Vogt MNP; Dennis JJ; Regimbal RJ; Bauer PR; Blair JE; Casadevall A; Carter RE; Joyner MJ
Nat Commun; 2021 Aug; 12(1):4864. PubMed ID: 34381030
[TBL] [Abstract][Full Text] [Related]
11. Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies.
Ferrari S; Caprioli C; Weber A; Rambaldi A; Lussana F
Leuk Lymphoma; 2021 Jun; 62(6):1490-1496. PubMed ID: 33461387
[TBL] [Abstract][Full Text] [Related]
12. COVID-19 in Patients with Hematologic Malignancies: Outcomes and Options for Treatments.
Martínez JC; Sica RA; Stockerl-Goldstein K; Rubinstein SM
Acta Haematol; 2022; 145(3):244-256. PubMed ID: 35134811
[TBL] [Abstract][Full Text] [Related]
13. Feasibility of Convalescent Plasma Therapy in Kidney Transplant Recipients With Severe COVID-19: A Single-Center Prospective Cohort Study.
Gupta A; Kute VB; Patel HV; Engineer DP; Banerjee S; Modi PR; Rizvi SJ; Mishra VV; Patel AH; Navadiya V
Exp Clin Transplant; 2021 Apr; 19(4):304-309. PubMed ID: 33605203
[TBL] [Abstract][Full Text] [Related]
14. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
Trials; 2021 May; 22(1):343. PubMed ID: 34001215
[TBL] [Abstract][Full Text] [Related]
15. Case Series: Convalescent Plasma Therapy for Patients with COVID-19 and Primary Antibody Deficiency.
Lang-Meli J; Fuchs J; Mathé P; Ho HE; Kern L; Jaki L; Rusignuolo G; Mertins S; Somogyi V; Neumann-Haefelin C; Trinkmann F; Müller M; Thimme R; Umhau M; Quinti I; Wagner D; Panning M; Cunningham-Rundles C; Laubner K; Warnatz K
J Clin Immunol; 2022 Feb; 42(2):253-265. PubMed ID: 34893946
[TBL] [Abstract][Full Text] [Related]
16. Convalescent Plasma for the Treatment of Severe COVID-19 Infection in Cancer Patients.
Tremblay D; Seah C; Schneider T; Bhalla S; Feld J; Naymagon L; Wang B; Patel V; Jun T; Jandl T; Rahman F; Liu STH; Aberg JA; Bouvier N;
Cancer Med; 2020 Nov; 9(22):8571-8578. PubMed ID: 32945149
[TBL] [Abstract][Full Text] [Related]
17. COVID-19 in pediatric cancer patients is associated with treatment interruptions but not with short-term mortality: a Polish national study.
Węcławek-Tompol J; Zakrzewska Z; Gryniewicz-Kwiatkowska O; Pierlejewski F; Bień E; Zaucha-Prażmo A; Zając-Spychała O; Szmydki-Baran A; Mizia-Malarz A; Bal W; Sawicka-Żukowska M; Kruk A; Ociepa T; Raciborska A; Książek A; Szczepański T; Peregud-Pogorzelski J; Krawczuk-Rybak M; Chaber R; Matysiak M; Wachowiak J; Irga-Jaworska N; Młynarski W; Dembowska-Bagińska B; Balwierz W; Matkowska-Kocjan A; Kazanowska B; Styczyński J; Ussowicz M
J Hematol Oncol; 2021 Oct; 14(1):163. PubMed ID: 34635137
[TBL] [Abstract][Full Text] [Related]
18. Successful early treatment combining remdesivir with high-titer convalescent plasma among COVID-19-infected hematological patients.
Weinbergerova B; Mayer J; Kabut T; Hrabovsky S; Prochazkova J; Kral Z; Herout V; Pacasova R; Zdrazilova-Dubska L; Husa P; Bednar P; Ruzek D; Lengerova M
Hematol Oncol; 2021 Dec; 39(5):715-720. PubMed ID: 34396566
[No Abstract] [Full Text] [Related]
19. A Retrospective Study on the Effects of Convalescent Plasma Therapy in 24 Patients Diagnosed with COVID-19 Pneumonia in February and March 2020 at 2 Centers in Wuhan, China.
Huang S; Shen C; Xia C; Huang X; Fu Y; Tian L
Med Sci Monit; 2020 Dec; 26():e928755. PubMed ID: 33264276
[TBL] [Abstract][Full Text] [Related]
20. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
